Abstract
Plastics have transformed the way we package products thanks to their versatility, strength, light weight, and affordability. Today, they are used across almost every industry, including food, cosmetics, electronics, and especially pharmaceuticals. In medicines, packaging is more than just a container it protects drugs, keeps them stable, and makes sure they can be stored and delivered safely. For this reason, plastics have largely replaced older materials like glass and metal. [1]They are commonly used as primary packaging that directly touches the product, such as bottles, blister packs, droppers, ampoules, and pre-filled syringes. These solutions help preserve the safety and effectiveness of medicines throughout their shelf life. [2]
According to market analyses, plastics currently account for approximately 53 % of primary pharmaceutical packaging materials globally. Notably, blister packs alone comprise around 30 % of this segment. However, the extensive reliance on plastics has raised increasing concerns regarding product degradation and contamination, particularly under adverse environmental conditions. During storage and transportation, pharmaceuticals are often subjected to fluctuating temperatures, varying humidity levels, and mechanical stresses. These factors may lead to the release of microplastics (MPs). These particles defined as plastic fragments smaller than 5 mm release from the packaging into the medication. [3] Such leachates can interact with active pharmaceutical ingredients (APIs), which are the substances in medicines that produce therapeutic effects by treating, preventing, or diagnosing disease, or by modifying physiological functions. This interaction can alter their chemical composition, stability, and therapeutics, posing significant health risks to patients. Plastics are not completely stable, and their breakdown can be accelerated under certain conditions such as high temperatures, UV exposure, or acidic and alkaline environments. This degradation can release a range of additives and residues, including plasticizers, stabilizers, solvents, and unreacted monomers. [4] The risks are particularly pronounced for liquid medicines like syrups, suspensions, and injectables, where even small amounts of contamination can destabilize the formulation. Alarmingly, studies have found microplastics (MPs) in over 70% of liquid pharmaceutical products exposed to stressed conditions. [2]